Bod Australia Limited Overview
Bod Science is a micro-cap Australian medicinal cannabis distributor that began life as a natural-health and skincare start-up and, between 2017 and 2023, repositioned itself as a "cannabis-centric" drug-development company. Its core franchise was MediCabilis, a GMP-certified, CBD-dominant medicinal cannabis oil supplied to prescribing doctors in Australia and the UK, complemented by consumer CBD/hemp wellness products (including the UK CBII brand and an exclusive supply relationship with Hong Kong-listed Health & Happiness Group) and an over-the-counter herbal range. Revenue peaked at A$6.6m in FY2021 before collapsing as the Australian market migrated to THC flower and the H&H exclusivity lapsed. An expensive Schedule 3 insomnia trial missed its primary endpoint in 2023, a capital raise failed in November 2023, and the company entered administration. Today it is a four-employee THC-flower distribution business (Bod Flora, FGW, MediCabilis) being absorbed into private grower Biortica Agrimed via a court-sanctioned DOCA share transfer.
Company's own description (latest annual report, FY2025)
The FY2025 Deed Administrator's Report defines the principal activity narrowly as the distribution of therapeutic medicinal cannabis products, based on GMP-certified cannabis extracts, for medical markets in Australia and the United Kingdom. This compares with the broader FY2023 description, which covered both (i) development and distribution of therapeutic medicinal cannabis products for medical markets in Australia and the UK and (ii) development of premium CBD and hemp products for consumer markets in Australia, the UK, Europe and the United States.
Independent characterisation
Bod has never manufactured at scale; it is an asset-light brand owner and distributor that outsources extraction, formulation and finished-goods manufacture to contract manufacturers and buys inventory (by FY2025, exclusively from Australian suppliers in AUD, per the FY2025 risk section). Its economic model has passed through three phases:
-
2014–2017: natural-health/OTC herbal brand owner. Imported European clinically-studied herbal extracts (e.g., Flexofytol turmeric extract for joint health; Sedistress passion-flower extract for stress/sleep) and distributed via pharmacy wholesalers.
-
2018–2023: cannabis-centric healthcare company. MediCabilis (CBD-dominant oil) sold under Australia's Special Access Scheme (SAS-B) and Authorised Prescriber pathways and in the UK via specials; CBD wellness products in the UK, EU (Netherlands) and US; white-label/exclusive CBD supply to Health & Happiness (H&H) Group; R&D tax-incentive-funded clinical programs (Phase I, Schedule 3 insomnia Phase IIb, long-COVID study) and a delivery-technology acquisition (Aqua Phase).
-
Dec 2023–present: THC-flower distributor under administration. First THC product launched in Australia in December 2023; 12 THC SKUs by FY2025; THC accounted for 73% of FY2025 medical sales; R&D, marketing and international operations essentially shut down; operating costs funded by Biortica.
Revenue model mix
| Revenue type (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Product sales – sale of goods (AUD M) | 3.425 | 1.668 | 0.865 | 1.485 |
| Royalty / licensing (AUD M) | 0.176 | 0.050 | 0.010 | 0 |
| Revenue from contracts with customers (AUD M) | 3.601 | 1.718 | 0.876 | 1.485 |
| R&D tax incentive (AUD M) | 1.338 | 1.357 | 1.981 | 0.678 |
| Biortica funding income (AUD M) | 0 | 0 | 0.967 | 1.171 |
Source: FY2023 Appendix 4E (Notes 4–6); FY2025 Appendix 4E (Notes 4–6). FY2023 reported R&D incentive within "revenue"; FY2024–FY2025 reclassified it to "other income". The company has no subscription or service revenue. Royalty income derived from the OTC CBD/Hemp segment (H&H-related arrangements).
Value-chain position, customers and end-markets
Value chain: Brand/IP owner and regulatory sponsor → contract GMP manufacturers (outsourced) → pharmaceutical wholesalers/distributors (Symbion, API historically; five distributors by FY2025) → pharmacies and prescribing clinics → patients.
Customer concentration: Three major customers accounted for 64% of FY2023 revenue (A$1.07m) and 67% of FY2025 sales revenue (A$1.00m); two major customers accounted for 61% of FY2024 sales (FY2023 and FY2025 Appendix 4E, Note 4).
End-markets (historic): Australian prescribed medicinal cannabis; UK prescribed medicinal cannabis (specials); UK/EU/US consumer CBD wellness; Australian OTC herbal supplements; China/Asia via H&H (indirect).
End-markets (current): Australian prescribed medicinal cannabis (THC flower and CBD oils); negligible UK residual sales (A$8,188 in FY2025).
Strategy
Stated strategy themes
FY2023 (pre-administration): Advance the medical cannabis division and R&D; commercialise the Schedule 3 CBD insomnia product through SAS-B and, on ARTG registration, through Australian pharmacies via an exclusive Arrotex Pharmaceuticals distribution agreement; commercialise Aqua Phase as a drug-delivery platform and license it outside cannabinoids; collaborate with Malaysia's Antah Group (LOI) on a clinical trial and commercialisation of medical cannabis in Malaysia; pursue new global distribution partners after H&H exclusivity expired.
FY2024–FY2026 (under administration): Preserve and grow the Australian medical cannabis business (THC flower pivot, new SKUs, more distributors); sell non-core IP; complete a restructuring with Biortica Agrimed providing "a sustainable source of debt and equity funding" (FY2025 report).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Status / outcome |
|---|---|---|
| Nov 2024 | Binding SPA to acquire Biortica via backdoor listing; Bod to be renamed "Biortica Agrimed Ltd" | Abandoned Nov 2025 |
| Nov 2024 | Sale of Aqua Phase, Schedule 3 data and CLIC Protein IP to Optimus Salvus (A$125,000 plus forgiveness of £2,000,000 debt claimed by Aqua Phase inventors) | Completed 21 Nov 2024 |
| FY2025 | THC portfolio expansion to 12 SKUs; distributors increased 2 → 5 | Completed; THC 73% of medical sales |
| FY2025 | Cost reduction: R&D -99%, marketing -96%, other expenses -67%, employee costs -59% | Completed |
| Nov 2025 | DOCA variation: compulsory transfer of all shares to Biortica under s 444GA | Court leave granted 19 Jun 2026 |
| 2,026 | DOCA completion; creditors' trust; retention of employees | Scheduled 30 Jun 2026; effectuation not publicly confirmed |
ESG/sustainability commitments and medium-term targets
No sustainability commitments, cost-program targets or medium-term financial targets have been published. No guidance has been issued since administration.
Products & Services
Medical segment
| Product / brand | Description | Target customer | Launch / status | Pricing |
|---|---|---|---|---|
| MediCabilis® | GMP-certified, CBD-dominant full-spectrum cannabis oil; flagship product; supplied under SAS-B/Authorised Prescriber in Australia and as unlicensed special in UK | Prescribing GPs/specialists; patients with chronic pain, anxiety, sleep and other unmet needs | First imports Mar 2018; first prescription Oct 2018; UK via PCCA from Jul 2019. Units shipped: 12,187 (FY2021), 7,182 (FY2022), 3,419 (FY2023). Still sold FY2025 but declining. | — |
| Bod Flora (THC range) | THC flower and THC-containing medicinal cannabis products | Australian prescribing clinics/patients | First THC product Dec 2023; 12 THC SKUs by FY2025; THC sales A$224,590 (FY2024), A$1,081,718 (FY2025, 73% of medical sales) | Not publicly disclosed; FY2025 discounting to clear slow-moving stock |
| FGW | Medicinal cannabis product range (named in FY2025 report alongside Bod Flora and MediCabilis); product specifics not disclosed | Australian patients | FY2025 | — |
| MediCabilis long-COVID application | Clinical study of MediCabilis for long-term COVID symptoms (announced FY2021) | — | Study status not disclosed after 2021 | — |
OTC CBD/Hemp segment (exited/dormant)
| Product / brand | Description | Market | Launch / status |
|---|---|---|---|
| CBII | Consumer CBD wellness range; four new products launched Apr 2020 | UK (later broadened UK footprint, Jun 2021) | Inactive by FY2024 |
| CBD products – Netherlands | Consumer CBD launch | Netherlands/EU | Oct 2020; EU sales A$390,103 (FY2022) falling to A$4,258 (FY2023) |
| CBD products – United States | GRAS status achieved Sep 2020; first binding PO Apr 2021 | US | US sales A$154,868 (FY2022), A$41,150 (FY2023), nil thereafter |
| H&H Group CBD/hemp supply | Exclusive supply/licence of CBD and hemp products to Health & Happiness (HKSE: 1112) | H&H brands (Swisse group) | Sales A$1,281,098 (FY2022), A$294,565 (FY2023); exclusivity expired; capitalised H&H product-development costs impaired A$152,596 (FY2023) |
| Schedule 3 low-dose CBD soft gel (insomnia) | Proprietary CBD soft-gel with patent-protected encapsulation intended for pharmacist-only sale; 50mg/100mg doses tested | Australian pharmacy consumers | Phase IIb missed primary endpoint (2023); A$500,000 received from initial commercialisation (Arrotex exclusive distribution agreement); IP and data sold to Optimus Salvus Nov 2024 |
OTC Herbals segment (exited early 2H FY2024)
| Product | Description | Status |
|---|---|---|
| Flexofytol | Clinically studied turmeric extract for joint health, cartilage ageing and mild-arthritis inflammation | Exited FY2024 |
| Sedistress | Passion-flower extract for stress, anxiety and insomnia symptoms | Exited FY2024 |
| Other natural-medicine portfolio stocked by API/Symbion (2018) | Not itemised in sources reviewed | Exited FY2024 |
Technology / IP assets (all sold)
| Asset | Description | Status |
|---|---|---|
| Aqua Phase | Process technology to increase bioavailability of lipophilic cannabinoids (oral CBD-in-oil bioavailability estimated at 6–8%); acquired for £1,000,000 (Aug 2023) with patent application | Impaired A$1,946,283 (FY2024); sold Nov 2024 |
| CLIC Protein IP | Not described in detail | Sold Nov 2024 |
| Soft gel/Schedule 3 clinical research and data | Woolcock Phase IIb data and dossier | Sold Nov 2024 |
Financial Narrative
Income statement
Sources: FY2021 results release (23 Aug 2021); FY2023 Appendix 4E (P&L, Note 7, Additional information); FY2025 Appendix 4E (P&L, Note 4, Additional information). EBITDA = EBIT + D&A (analyst calculation; not a company-reported metric). FY2021 sub-lines not available in primary sources reviewed. FY2020 net loss A$4.82m and FY2019 net loss A$7.62m (FY2020 release) for context.
Margins and growth
All margins on revenue from contracts with customers. FY2022 gross margin depressed by a one-off manufacturing cost; the company stated an underlying FY2022 gross margin of 33% vs 41% in FY2023. Revenue CAGR FY2021–FY2025: -31.2% (A$6.643m → A$1.485m).
Balance sheet
FY2021 equity and cash are the 1 July 2021 opening balances disclosed in the FY2023 statement of changes in equity and FY2022 cash flow statement. Of FY2025 trade payables of A$5.81m, A$1.17m were DOCA trading liabilities; the remainder largely represents pre-administration creditor claims compromised by the DOCA.
Cash flow
FY2024 intangibles capex of A$1.94m is predominantly the £1m Aqua Phase acquisition, impaired in the same year. FY2021 cash flows not available in sources reviewed; the Dec 2020 A$8m placement (gross) funded FY2021–FY2022 burn.
Ratios
ROE is not meaningful from FY2023 (negative equity); debt/equity not meaningful from FY2023; ROIC, net debt/EBITDA and interest coverage not meaningful in any year because EBIT and EBITDA were negative through FY2024 and FY2025 EBIT is driven by non-trading income; cash conversion cycle not computed because trade receivables and payables are distorted by DOCA-compromised claims. ROA and asset turnover use average total assets.
Commentary on trends, inflections and drivers
Revenue. The FY2020–FY2021 peak (A$6.1m and A$6.6m contract revenue) reflected two engines firing simultaneously: MediCabilis prescription growth (12,187 units in FY2021, up 212%) and CBD wellness sales of A$4.39m in FY2021, heavily weighted to H&H. Both engines then failed. Prescribing in Australia shifted decisively from CBD oils to THC flower, a trend management explicitly cited in FY2023 when MediCabilis units halved to 3,419; UK medical sales were also hit by supply-chain problems. Separately, the H&H exclusivity lapsed, removing roughly A$1.0m of high-volume (but lower-margin) sales between FY2022 and FY2023. The FY2025 rebound (+70%) is real but small, and reflects a late pivot into THC flower and expansion from two to five distributors.
Profitability. Bod never generated an operating profit from trading. The FY2023 loss widened to A$7.95m because R&D more than doubled to A$3.46m (Woolcock Phase IIb and Aqua Phase pharmacokinetic work) while revenue fell by half. FY2024's A$6.41m loss included A$3.33m of impairments (Aqua Phase A$1.95m, right-of-use asset A$1.30m, patents A$0.09m). The FY2025 profit of A$0.26m is an artefact of administration: Biortica funding income (A$1.17m), residual R&D incentives (A$0.68m) and the A$0.125m IP sale gain offset a medical segment that still lost A$0.43m.
Balance sheet. Equity swung from +A$8.7m (July 2021) to -A$5.3m (June 2024). The company was insolvent from about 30 June 2023 on the Deed Administrator's analysis accepted by the Court. The going-concern note in the FY2023 accounts already relied on further raises, borrowings (including Radium Capital R&D-advance loans) and Aqua Phase monetisation, none of which materialised.
Cash. Operating cash burn of A$4–6m a year against a sub-A$10m market capitalisation forced repeated dilutive raises at falling prices (A$0.08 in FY2023 vs highs of A$0.74 in FY2021). The failure of the November 2023 placement was the proximate trigger for administration.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (AUD Mn)
| Segment revenue (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Medical | 1.790 | 0.933 | 0.610 | 1.485 |
OTC CBD/Hemp (incl. royalty and other) | 1.457 | 0.589 | 0.010 | 0 |
OTC Herbals | 0.495 | 0.440 | 0.255 | 0 |
Corporate (R&D incentive, interest, other income) | 1.539 | 1.690 | 0 | 0 |
Segment sales of goods + royalty (AUD Mn)
| Segment sales of goods + royalty (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Medical | 1.649 | 0.933 | 0.610 | 1.485 |
OTC CBD/Hemp | 1.457 | 0.345 | 0.010 | 0 |
OTC Herbals | 0.495 | 0.440 | 0.255 | 0 |
Total | 3.601 | 1.718 | 0.876 | 1.485 |
% contribution to revenue from contracts (%)
| % contribution to revenue from contracts (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Medical (%) | 45.8 | 54.3 | 69.7 | 100.0 |
OTC CBD/Hemp (%) | 40.5 | 20.1 | 1.2 | 0.0 |
OTC Herbals (%) | 13.7 | 25.6 | 29.1 | 0.0 |
YoY growth in segment sales (%)
| YoY growth in segment sales (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Medical (%) | -43.4 | -34.6 | 143.4 |
OTC CBD/Hemp (%) | -76.3 | -97.0 | -100.0 |
OTC Herbals (%) | -11.0 | -42.0 | -100.0 |
Segment profit/(loss) before tax (AUD Mn)
| Segment profit/(loss) before tax (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Medical | -0.913 | -1.418 | -1.125 | -0.433 |
OTC CBD/Hemp | -1.161 | -0.270 | 0.074 | -0.142 |
OTC Herbals | -0.368 | -0.427 | -0.103 | 0 |
Corporate | -2.964 | -5.838 | -5.259 | 0.834 |
Group | -5.407 | -7.953 | -6.413 | 0.259 |
Segment pre-tax margin on segment sales (%)
| Segment pre-tax margin on segment sales (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Medical (%) | -55.4 | -151.9 | -184.4 | -29.2 |
OTC Herbals (%) | -74.5 | -97.1 | -40.3 | — |
Group Entities
| Entity | Jurisdiction | Status |
|---|---|---|
Bod Science Limited (parent) | Australia | Subject to DOCA; delisted 1 Dec 2025 |
Bod Healthcare Ltd | United Kingdom | Dissolved 12 Aug 2025 |
Aqua Phase Ltd (subsidiary of Bod Healthcare Ltd) | United Kingdom | Incorporated (acquired as dormant shelf) 3 Aug 2023; dissolved 10 Dec 2024 |
Other subsidiaries | Not individually disclosed in sources reviewed | The FCA judgment describes an "international group" whose subsidiaries' equity was valued at nil |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue from contracts with customers (AUD Mn) | 6.643 | 3.601 | 1.718 | 0.876 | 1.485 |
Revenue incl. other revenue, legacy presentation (AUD Mn) | 7.420 | 5.080 | 3.321 | — | — |
Revenue YoY growth (%) | — | -45.8 | -52.3 | -49.0 | 69.6 |
Cost of sales – raw materials and consumables (AUD Mn) | — | 2.926 | 1.022 | 0.610 | 1.147 |
Gross profit (AUD Mn) | — | 0.674 | 0.696 | 0.266 | 0.338 |
R&D expense (AUD Mn) | — | 1.681 | 3.462 | 1.206 | 0.018 |
Employee/director benefits (AUD Mn) | — | 3.285 | 3.048 | 1.968 | 0.816 |
Impairments – intangibles, ROU, inventory, receivables (AUD Mn) | — | 0.022 | 0.280 | 3.439 | 0.179 |
Operating income / EBIT (AUD Mn) | — | -5.412 | -7.941 | -6.276 | 0.288 |
Depreciation and amortisation (AUD Mn) | — | 0.154 | 0.172 | 0.209 | 0.024 |
EBITDA (AUD Mn) | — | -5.258 | -7.769 | -6.067 | 0.312 |
Interest expense (AUD Mn) | — | 0 | 0.027 | 0.152 | 0.050 |
Pre-tax income (AUD Mn) | -4.226 | -5.407 | -7.953 | -6.413 | 0.259 |
Income tax (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net income (AUD Mn) | -4.226 | -5.407 | -7.953 | -6.413 | 0.259 |
EPS basic (AUD cents) | -4.26 | -5.10 | -5.63 | -3.68 | 0.15 |
EPS diluted (AUD cents) | -4.26 | -5.10 | -5.63 | -3.68 | 0.15 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | — | 18.7 | 40.5 | 30.4 | 22.7 |
Operating (EBIT) margin (%) | — | -150.3 | -462.2 | -716.8 | 19.4 |
EBITDA margin (%) | — | -146.0 | -452.2 | -692.9 | 21.0 |
Net margin (%) | -63.6 | -150.1 | -462.9 | -732.4 | 17.4 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | — | 5.313 | 3.504 | 2.307 | 2.597 |
Cash and equivalents, gross (AUD Mn) | 8.053 | 3.666 | 2.031 | 0.434 | 1.098 |
Short-term borrowings / overdraft (AUD Mn) | — | 0 | 0.963 | 0.460 | 0.461 |
Lease liabilities, current (AUD Mn) | — | 0 | 0 | 1.370 | 1.141 |
Long-term debt (AUD Mn) | — | 0 | 0 | 0 | 0 |
Net debt incl. leases (AUD Mn) | — | -3.666 | -1.068 | 1.396 | 0.505 |
Trade and other payables (AUD Mn) | — | 1.341 | 1.654 | 5.446 | 5.814 |
Total liabilities (AUD Mn) | — | 1.847 | 4.207 | 7.625 | 7.751 |
Total equity (AUD Mn) | 8.661 | 3.467 | -0.703 | -5.318 | -5.154 |
Goodwill (AUD Mn) | — | 0 | 0 | 0 | 0 |
Intangibles (AUD Mn) | — | 0.415 | 0.131 | 0.022 | 0.003 |
Inventories (AUD Mn) | — | 0.556 | 0.289 | 0.671 | 0.408 |
Working capital (AUD Mn) | — | 3.099 | -0.320 | -5.298 | -5.099 |
Accumulated losses (AUD Mn) | 23.884 | 29.291 | 37.244 | 41.029 | 40.626 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | -4.176 | -5.678 | -0.914 | 0.937 |
Capex – PP&E plus intangibles (AUD Mn) | — | 0.207 | 0.148 | 1.959 | 0 |
Free cash flow (AUD Mn) | — | -4.384 | -5.826 | -2.873 | 0.937 |
Equity raised, net (AUD Mn) | — | 0 | 3.202 | 1.784 | 0 |
Borrowings raised, net (AUD Mn) | — | 0 | 0.936 | 0.183 | 0 |
Borrowings repaid (AUD Mn) | — | 0 | 0 | 1.121 | 0 |
R&D incentive received (AUD Mn) | — | 1.153 | 1.513 | 2.010 | 0.678 |
Biortica funding received in cash (AUD Mn) | — | 0 | 0 | 0.967 | 0.923 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (%) | -89.2 | — | — | — |
ROA (%) | — | -180.4 | -220.7 | 10.6 |
Current ratio (x) | 2.74 | 0.91 | 0.30 | 0.34 |
Debt/equity (x) | 0 | — | — | — |
Asset turnover (x) | — | 0.39 | 0.30 | 0.61 |
Region – sales to external customers (AUD Mn)
| Region – sales to external customers (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Australia | 1.998 | 1.314 | 0.778 | 1.477 |
United Kingdom | 0.882 | 0.309 | 0.098 | 0.008 |
European Union | 0.390 | 0.004 | 0 | 0 |
United States | 0.155 | 0.041 | 0 | 0 |
Total | 3.425 | 1.668 | 0.876 | 1.485 |
Regional YoY growth
| Regional YoY growth | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Australia (%) | -34.3 | -40.8 | 89.9 |
United Kingdom (%) | -64.9 | -68.3 | -91.6 |
European Union (%) | -98.9 | -100.0 | 0.0 |
United States (%) | -73.4 | -100.0 | 0.0 |
Regional share of sales (%)
| Regional share of sales (%) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Australia (%) | 58.3 | 78.8 | 88.8 |
United Kingdom (%) | 25.7 | 18.5 | 11.2 |
European Union (%) | 11.4 | 0.3 | 0.0 |
United States (%) | 4.5 | 2.5 | 0.0 |
Per-Share Data
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
Share price at 30 June (AUD cents) | 34.0 | 27.0 | 33.5 | 7.0 | 6.9 | 2.4 | 2.4 |
Share price high (AUD cents) | 66.0 | 72.0 | 74.0 | 36.0 | 17.0 | 12.5 | 2.4 |
Share price low (AUD cents) | 22.0 | 12.0 | 25.5 | 7.0 | 4.6 | 2.4 | 2.4 |
Loss/profit per share (AUD cents) | -11.59 | -5.40 | -4.26 | -5.10 | -5.63 | -3.68 | 0.15 |
Share Price & Returns
| Date | Raise | Price |
|---|---|---|
Sep 2018 | A$6.4m strategic placement | — |
Aug 2019 | A$1.2m option exercise (board/management) | — |
Dec 2020 | A$8m private placement | — |
Sep–Oct 2022 | A$3.5m (A$1.5m placement + A$2.0m entitlement) | A$0.08 |
Aug 2023 | A$1.9m placement (with 1-for-2 options at A$0.10) | A$0.08 |
FY2024 total | A$1.78m net equity raised | — |
Nov 2023 | Placement announced; failed | — |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance and consensus
No guidance has been issued since entering administration, and there is no analyst consensus. The only forward-looking statement is Biortica's written representation (22 Sep 2025) that planned capital raises and forecast revenue growth would provide positive cash flow sufficient to fund the combined group (FY2025 going-concern note).
Bull-case arguments (for the operating business under Biortica ownership)
-
THC momentum: Medical sales grew 143% in FY2025 with THC at 73% of the mix; integration with a large-scale grower could convert this into a supply-advantaged brand.
-
Clean slate: The DOCA extinguishes ~A$4.6m of legacy payables into a creditors' trust, leaving a near debt-free operating company with positive FY2025 operating cash flow.
-
Minimal fixed costs: A four-person team and near-zero R&D/marketing spend mean incremental sales should flow through at improved margins once inventory clearance ends.
Bear-case arguments
-
Sub-scale and still loss-making at segment level: Medical lost A$0.43m in FY2025; FY2025 group profit depended on A$1.17m of funder support.
-
Margin compression: Gross margin fell to 23% in a price-competitive THC flower market.
-
Execution risk at the acquirer: Biortica repeatedly missed ASX/audit conditions, forcing at least three DOCA extensions and abandonment of the relisting.
Catalysts and monitorables (next 12 months)
-
Confirmation of DOCA effectuation and share transfer to Biortica (scheduled 30 Jun 2026).
-
Creditors' trust distributions (unsecured 1.10–2.59 cents in the dollar; priority employees 100 cents).
-
Issue of capital-loss declaration to former shareholders.
-
Any renaming, rebranding or integration announcements by Biortica.
-
Any Biortica capital raise or alternative listing plan.
-
Removal of residual security registrations (e.g., Burleigh Heads Cannabis).
Concluding analyst verdict
Bod Australia (Bod Science) is a case study in how a first-mover small-cap can be undone by a market shift it did not control and a capital structure it could not sustain. Between 2018 and 2021 the company built genuine prescriber recognition for MediCabilis, assembled credible distribution (Symbion, API, PCCA) and secured a high-profile partner in Health & Happiness. Revenue reached A$6.6m in FY2021. But the model rested on CBD at precisely the moment Australian prescribing pivoted to THC flower, and on a single large customer whose exclusivity lapsed. Instead of retrenching, management doubled R&D in FY2023 to pursue a Schedule 3 insomnia product whose pivotal trial then missed its primary endpoint, and committed £1m to the Aqua Phase technology weeks before a funding round failed. The resulting insolvency, dated by the Deed Administrator to about June 2023, wiped out more than A$40m of accumulated shareholder capital.
For former equity holders the outcome is final: the Federal Court accepted an independent valuation of nil and granted leave to transfer every share and option to Biortica Agrimed without consideration. There is no residual investment case in the listed security, which no longer exists.
For creditors, suppliers, competitors and potential partners, the relevant question is whether the operating business, now a four-person THC-flower distributor with A$1.5m of revenue, has a future inside Biortica. The FY2025 numbers show real top-line momentum and positive operating cash flow, but segment-level trading remains loss-making, margins are thin and the business is wholly dependent on its new owner's funding and execution, which has been inconsistent. The most likely trajectory is absorption into Biortica as a downstream brand and distribution channel rather than revival as a standalone company. Stakeholders should monitor DOCA effectuation, creditor distributions and any Biortica capital-raising disclosures.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background / education | FY2023 total remuneration (AUD) | FY2025 total remuneration (AUD) |
|---|---|---|---|---|---|
Joanne (Jo) Patterson | Founder, CEO and Executive Director; Company Secretary since 6 May 2025 | Founded 2014; CEO agreement from 5 Sep 2016 | MBus (Marketing), University of Technology Sydney; 20+ years across technology, advertising and beauty businesses | 524,465 | 154,321 |
David Baker | Non-Executive Chairman; Chair, Audit & Risk | Joined FY2022 | BA, LLB (Hons); 40+ years law, investment banking; co-founder Baker Cook Advisory; former director Mineral Commodities Ltd | 89,368 | 0 |
George Livery | Non-Executive Director; Chair, Remuneration & Nominations | Since ~2018 | FAMI; ex-CEO Village Cinemas Australia; Commercial Director Swisse; led Swisse integration into H&H; former Chair, Hydration Pharmaceutical Co. (retired May 2024) | 66,186 | 0 |
Akash Bedi | Non-Executive Director (H&H nominee in substance) | Since ~Dec 2020 | BEng (Manipal), MBA (Cardiff); Chief Strategy & Operations Officer, Health & Happiness International; ex-HSBC M&A; director, Else Nutrition | 66,186 | 0 |
Craig Weller | Chief Technology Officer | Since 5 Sep 2016 | — | 432,810 | 146,291 |
Adrian Sturrock | Chief Financial Officer | 2 Aug 2021 – resigned 2025 (after ~4 years; exact date not confirmed) | — | 414,341 | 325,832 |
Hanno Cappon | Non-Executive Director | Resigned 9 Nov 2022 | — | 19,095 | — |
Carlie Hodges | Company Secretary | 23 Jan 2023 – 6 May 2025 | Corporate lawyer; FGIA | — | — |
Former NEDs (FY2022): Mark Masterson, Simon O'Loughlin, Patrice Malard | Non-Executive Directors | Departed during FY2022 | — | FY2022: 62,315 / 39,377 / 11,049 | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Component (AUD) | Patterson FY2023 | Patterson FY2025 | Weller FY2023 | Weller FY2025 | Sturrock FY2023 | Sturrock FY2025 |
|---|---|---|---|---|---|---|
Cash salary | 372,766 | 125,000 | 308,636 | 125,000 | 288,952 | 292,485 |
Cash bonus | 72,526 | 0 | 61,014 | 0 | 57,481 | 0 |
Superannuation | 22,948 | 14,375 | 24,267 | 14,375 | 24,672 | 30,000 |
Share-based payments | 47,448 | 9,443 | 48,466 | 6,873 | 36,711 | 6,475 |
Total | 524,465 | 154,321 | 432,810 | 146,291 | 414,341 | 325,832 |
Major Shareholders
| Holder | Shares | % | Source / date |
|---|---|---|---|
HSBC Custody Nominees (Australia) Ltd | 29,061,130 | 16.39 | Market Index top holders (latest register) |
SG Hiscock & Company Ltd | 10,416,351 | 8.53 (at time of notice; ~5.9% of current 177.3m shares) | Substantial holder notice 20 Sep 2023 |
Jo Patterson (CEO) | 7,175,000 | 4.05 | FY2025 report |
David Baker (Chair) | 6,375,000 | 3.59 | FY2025 report |
Health And Beauty Enterprise Pty Ltd | 6,375,000 | 3.59 | Market Index / Motley Fool top holders (ceased substantial holding 22 Aug 2023) |
Craig Weller (CTO) | 4,852,329 | 2.74 | FY2025 report |
Citicorp Nominees Pty Ltd | 4,506,536 | 2.57 | Motley Fool top holders |
George Livery | 395,295 | 0.22 | FY2025 report |
Adrian Sturrock | 300,000 | 0.17 | FY2025 report |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning vs Bod |
|---|---|---|---|
Medical cannabis (AU) | Montu / Alternaleaf | Private telehealth-plus-supply platform | Far larger; vertically integrated patient acquisition, dominant in THC flower prescribing |
Medical cannabis (AU) | Little Green Pharma (ASX: LGP) | Listed grower/manufacturer | Own cultivation and GMP manufacture; far larger scale |
Medical cannabis (AU) | Cann Group (ASX: CAN) | Listed grower/manufacturer | Large-scale cultivation assets |
Medical cannabis (AU) | Vitura Health (ASX: VIT) | Listed clinic/distribution platform | Larger distribution and clinic network |
Medical cannabis (AU) | Australian Natural Therapeutics Group | Private cultivator/brand owner | Larger THC flower supplier |
Medical cannabis (AU) | Cannatrek | Private cultivator/brand | Larger THC flower supplier |
Medical cannabis (AU) | Biortica Agrimed / Apollo Green | Private B2B grower and genetics (self-described as Australia's largest vertically integrated commercial grower of medicinal plants) | Acquirer; supply-side partner |
Medical cannabis (AU) | Zelira Therapeutics, Emyria (ASX: EMD) | Listed drug-development/clinic models | Comparable small-cap, R&D-led positioning |
Medical cannabis (UK) | Health House International and UK specials suppliers | Distributors | Larger UK footprint |
Consumer CBD (UK/EU/US) | Numerous private CBD brands | Fragmented consumer market | Bod exited |
S3 CBD (AU) | Other sponsors pursuing S3 low-dose CBD registration | Pharma sponsors | No S3 CBD product reached Bod's market; Bod exited |
OTC herbals (AU) | Blackmores, Swisse (H&H) and other VMS brands | Large VMS companies | Bod's herbal range was sub-scale and exited |
Recent Developments
Because the company was suspended and in administration throughout this window, material disclosures were sparse. The register extends back to late 2024 to provide context.



